Literature DB >> 11478753

Helicobacter pylori and risk for gastric adenocarcinoma.

R J Asghar1, J Parsonnet.   

Abstract

Gastric cancer is the second most common cause of cancer death in the world. Helicobacter pylori infection is now a well-accepted cause of this malignancy; in some parts of the world, up to eighty percent of all gastric cancers are at least in part caused by H. pylori infection. H. pylori infection typically starts in childhood as an inflammatory process in the stomach. The changes in the gastric microenvironment facilitate gastric cancer over time. Among infected individuals, genotype of H. pylori, coincident environmental exposures, and genetic factors of host seem to play roles in determining who will get gastric cancer and who will not. Unfortunately, it remains unknown whether treatment of H. pylori prevents gastric cancer. Thus, screening for H. pylori to prevent cancer is not yet widely recommended. Some consensus groups, however, have recommended screening for and treating H. pylori infection in individuals with family histories of gastric malignancy. In high-risk countries, screening programs for early gastric cancer itself may improve therapeutic outcome for this highly lethal disease.

Entities:  

Mesh:

Year:  2001        PMID: 11478753

Source DB:  PubMed          Journal:  Semin Gastrointest Dis        ISSN: 1049-5118


  10 in total

1.  What lurks beneath: IL-11, via Stat3, promotes inflammation-associated gastric tumorigenesis.

Authors:  Juanita L Merchant
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

2.  The relationship between periodontal disease attributes and Helicobacter pylori infection among adults in the United States.

Authors:  Bruce A Dye; Deanna Kruszon-Moran; Geraldine McQuillan
Journal:  Am J Public Health       Date:  2002-11       Impact factor: 9.308

3.  Experimental infection of pigs with 'Candidatus Helicobacter suis'.

Authors:  A Hellemans; K Chiers; A Decostere; M De Bock; F Haesebrouck; R Ducatelle
Journal:  Vet Res Commun       Date:  2007-05       Impact factor: 2.459

4.  Evaluation of antibiotic treatment against "Candidatus Helicobacter suis" in a mouse model.

Authors:  A Hellemans; A Decostere; F Haesebrouck; R Ducatelle
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

5.  Hybrid vs sequential therapy for eradication of Helicobacter pylori in Taiwan: A prospective randomized trial.

Authors:  Kuan-Yang Chen; Tsung-Jung Lin; Chin-Lin Lin; Hsi-Chang Lee; Chung-Kwe Wang; Deng-Chyang Wu
Journal:  World J Gastroenterol       Date:  2015-09-28       Impact factor: 5.742

6.  Species of the family Helicobacteraceae detected in an Australian sea lion (Neophoca cinerea) with chronic gastritis.

Authors:  Andrew P A Oxley; Mark Powell; David B McKay
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

7.  Dietary Habits, demographical, and socio-economical risk factors of the newly diagnosed gastric cancers in the Eastern Anatolia Region of Turkey: an endemic upper gastrointestinal cancer region.

Authors:  Dogan Nasır Binici; Timur Koca; Hakan Dursun
Journal:  Dig Dis Sci       Date:  2009-12       Impact factor: 3.199

8.  Gastric transitional zones, areas where Helicobacter treatment fails: results of a treatment trial using the Sydney strain mouse model.

Authors:  Sander J O Veldhuyzen van Zanten; Tassia Kolesnikow; Vincent Leung; Jani L O'Rourke; Adrian Lee
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

9.  Performance of Routine Helicobacter pylori Invasive Tests in Patients with Dyspepsia.

Authors:  Hsi-Chang Lee; Ting-Chang Huang; Chin-Lin Lin; Kuan-Yang Chen; Chung-Kwe Wang; Deng-Chyang Wu
Journal:  Gastroenterol Res Pract       Date:  2013-12-18       Impact factor: 2.260

10.  H. pylori virulence factor CagA increases intestinal cell proliferation by Wnt pathway activation in a transgenic zebrafish model.

Authors:  James T Neal; Tracy S Peterson; Michael L Kent; Karen Guillemin
Journal:  Dis Model Mech       Date:  2013-03-01       Impact factor: 5.758

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.